New trial shows immunotherapy post-surgery improves overall survival for kidney cancer

  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 45 sec. here
  • 7 min. at publisher
  • 📊 Quality Score:
  • News: 38%
  • Publisher: 51%

Medicine Research News News

Medicine Research,Health Research News,Health Research

For the first time in fifty years, results from a Phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.

New trial shows immunotherapy post-surgery improves overall survival for kidney cancer retrieved 17 April 2024 from https://medicalxpress.com/news/2024-04-trial-immunotherapy-surgery-survival-kidney.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.New study uncovers why boys born to mothers with HIV are at greater risk of health problems and death in infancyUse this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page.

Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 101. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Saruparib demonstrates early efficacy in breast cancers with DNA repair defects in Phase I/II trialThe first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.
Source: medical_xpress - 🏆 101. / 51 Read more »